3ggv: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:3ggv.png|left|200px]] | |||
[[Image:3ggv. | |||
{{STRUCTURE_3ggv| PDB=3ggv | SCENE= }} | {{STRUCTURE_3ggv| PDB=3ggv | SCENE= }} | ||
===HIV Protease, pseudo-symmetric inhibitors=== | ===HIV Protease, pseudo-symmetric inhibitors=== | ||
{{ABSTRACT_PUBMED_19323562}} | {{ABSTRACT_PUBMED_19323562}} | ||
==About this Structure== | ==About this Structure== | ||
[[3ggv]] is a 9 chain structure of [[Virus protease]] with sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3GGV OCA]. | |||
==See Also== | |||
*[[Virus protease|Virus protease]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:019323562</ref><references group="xtra"/> | ||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
[[Category: Stoll, V S.]] | [[Category: Stoll, V S.]] | ||
| Line 30: | Line 21: | ||
[[Category: Protease]] | [[Category: Protease]] | ||
[[Category: Pseudo-symmetric inhibitor]] | [[Category: Pseudo-symmetric inhibitor]] | ||
Revision as of 13:36, 27 July 2012
HIV Protease, pseudo-symmetric inhibitorsHIV Protease, pseudo-symmetric inhibitors
Template:ABSTRACT PUBMED 19323562
About this StructureAbout this Structure
3ggv is a 9 chain structure of Virus protease with sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Degoey DA, Grampovnik DJ, Flentge CA, Flosi WJ, Chen HJ, Yeung CM, Randolph JT, Klein LL, Dekhtyar T, Colletti L, Marsh KC, Stoll V, Mamo M, Morfitt DC, Nguyen B, Schmidt JM, Swanson SJ, Mo H, Kati WM, Molla A, Kempf DJ. 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects. J Med Chem. 2009 Apr 23;52(8):2571-86. PMID:19323562 doi:http://dx.doi.org/10.1021/jm900044w